Gary K. Lee - 11 Aug 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Scientific Officer
Signature
/s/ Allison Peth, Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
11 Aug 2025
Transactions value $
-$2,785
Form type
4
Filing time
13 Aug 2025, 21:08:15 UTC
Previous filing
26 Feb 2025
Next filing
22 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lee Gary K. Chief Scientific Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO /s/ Allison Peth, Attorney-in-Fact 13 Aug 2025 0001907345

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Sale -$1,378 -131 -1.42% $10.53 9,093 11 Aug 2025 Direct F1, F2, F3, F4
transaction LYEL Common Stock Sale -$1,405 -136 -1.5% $10.34 8,957 12 Aug 2025 Direct F5, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F3 Includes 390 shares acquired on May 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.
F4 On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
F5 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
F6 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F7 On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.